Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy During Active Chemotherapy
Mavacamten can substantially improve quality of life in oHCM, even in patients with active malignancy.
Authors
- Teresa López‐Fernández (ORCID: https://orcid.org/0000-0002-3414-7022)
- Silvia Valbuena-López (ORCID: https://orcid.org/0000-0002-6252-4390)
- Juan Caro‐Codón (ORCID: https://orcid.org/0000-0002-0466-7633)
- Elena Refoyo Salicio (ORCID: https://orcid.org/0000-0003-4910-9827)
- Luis Fernández García-Moya
- Jesús Saldaña García (ORCID: https://orcid.org/0000-0002-1712-4654)
- Raúl Moreno (ORCID: https://orcid.org/0000-0001-7179-1426)
- I. Ghanem Cañete
- J.P. Perez Wert
- Maria Paños-Babin
Institutions
- Hospital La Paz Institute for Health Research (ES)
Publication Details
- Journal
- JACC Case Reports
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1016/j.jaccas.2025.106281
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00